SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Immunomedics (IMMU) - moderated

20 Oct 2022 10:42 PM
18 Dec 2020 06:56 PM
02 Sep 2020 07:03 PM
28 Aug 2020 10:59 PM
19 Aug 2020 02:21 PM
17 Jul 2020 01:47 PM
29 Jun 2020 11:30 AM
06 May 2020 09:45 PM
06 May 2020 02:45 PM
06 May 2020 01:08 PM
28 Nov 2018 06:58 PM
27 Nov 2018 10:59 PM
16 Aug 2018 01:37 PM
02 Aug 2018 02:20 PM <--
02 Aug 2018 12:37 PM
18 Jul 2018 10:49 AM
23 May 2018 11:21 PM
15 Dec 2016 12:56 PM
24 Aug 2014 10:16 AM
13 Jun 2013 08:03 AM
05 Jul 2011 10:42 AM
13 Oct 2010 10:05 AM
10 Oct 2010 10:39 AM
08 Mar 2010 08:32 AM
25 Nov 2009 03:28 PM
27 Oct 2009 09:05 PM
25 Oct 2009 06:57 PM
29 May 2009 02:59 PM
01 Mar 2009 10:32 AM
28 Nov 2007 08:09 PM
09 Apr 2007 08:32 PM
15 Feb 2007 09:40 PM
07 Jan 2007 10:29 AM
12 Dec 2006 08:08 AM
08 Nov 2006 09:32 PM
08 Oct 2006 07:47 PM
05 Oct 2006 07:43 AM
09 Sep 2006 08:57 PM

Return to Immunomedics (IMMU) - moderated
 
Welcome to the moderated message board for Immunomedics (IMMU). After watching several other forums degenerate, a number of us decided to start this board to get away from the trolls.

IMMU is in a very exciting phase, one that promises real benefits for patients.

As far as the company is concerned:
- the proxy fight is over
- the new management is delivering on the stated plan
- the BLA for TNBC has been accepted by the FDA, target action date is January 18, 2019.
- there are other possible indications for Sacituzumab Govitecan (IMMU-132).
- the share price has enjoyed a very nice run-up since January 2017
- for the first time in a long time there's quite a bit of cash in the bank
- IMMU is building out staff, the expectation is that sales cycles start in late 2018

The above doesn't include other drug candidates, possible partnerships and the like. With the above in mind, here are links to a few posts, resources, and sites you might want to peruse:

- IMMU's status:
-- Company website:
-- News release about BLA for TNBC being accepted:
-- Staff build-out:
-- Company goal (stand-alone biopharma): Msg # 46214
-- Other irons in the fire besides TNBC: Msg # 45237
-- BLA approval timeline is Q1, 2019.

- Thoughts on this year's ASCO presentation (June 3, 2018):
-- Msg # 45911
-- Msg # 45929

- Buyout rumors and why they're almost, but not quite totally, a waste of electrons: Msg # 46157

Etiquette:

This board is moderated, meaning the moderator (me) can stop people from posting here if they violate our norms. What are "our norms"? Well, be adult, play nice about sums it up. There are three responses I encourage for keeping the discussion civil and useful when you encounter a post that annoys you. In order of preference:

1> report a ToU violation to the SI admins via the link at the bottom of each post, they're good at dealing with problems.

2> send the person who posted a private message and work it out. Privately.

3> send me a private message. Wait a couple of days before doing so please, I'll usually see the message in that time frame and act (or not).

We strongly discourage any public discussion about poster's motivations, etc.

Please consider becoming a paid member. The SI admins do a very good job at keeping this board useful/fun. If you derive value from this forum, then SI deserves your support!

Finally, we all have internet connections and the like, please just skip all the breathless "It's up/down $X.Y in the first hour!" posts. We generally find it un-helpful to speculate on short-term price moves, let's just wait for all that until after the market closes.

Again, welcome! I think you'll find this a place to learn about and contribute to others' understanding of IMMU and its prospects.

Best,
Erick